Renal interstitial cells, proteinuria and progression of lupus nephritis: New frontiers for old factors

Lupus

Volumn 17, Issue 6, 2008, Pages 533-540

  Ferraccioli, G ^a,c   Romano, G ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

Hepatocyte growth factor; Interstitial damage; Prognosis; Systemic lupus erythematosus; Transforming growth factor 1

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; ALBUMIN; ALITRETINOIN; AUTOANTIBODY; CIGLITAZONE; DNA ANTIBODY; DOUBLE STRANDED DNA; ENDOTHELIAL PROTEIN C RECEPTOR; ENDOTHELIN 1; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; SCATTER FACTOR; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA1; TROGLITAZONE; VON WILLEBRAND FACTOR;

ANGIOGENESIS; APOPTOSIS; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DISEASE COURSE; ENDOTHELIUM CELL; GLOMERULONEPHRITIS; HUMAN; HYPOXIA; IMMUNOCOMPETENT CELL; INFLAMMATION; INFLAMMATORY CELL; KIDNEY CELL; KIDNEY FIBROSIS; KIDNEY TUBULE CELL; LUPUS ERYTHEMATOSUS NEPHRITIS; NEPHRON; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANOXIA; APOPTOSIS; DISEASE PROGRESSION; ENDOTHELIUM; HEPATOCYTE GROWTH FACTOR; HUMANS; INFLAMMATION; ISCHEMIA; KIDNEY TUBULES; LUPUS NEPHRITIS; PROTEINURIA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 46849096491     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203307088002     Document Type: Review

References (62)

1. Dooley, MA, Hogan, S, Jennette, C, Falk, R. Cyclophosphamidc therapy for lupus nephritis: poor renal survival in Black Americans. Glomerular Disease Collaborative Network. Kidney Int 1997; 51: 1188-1195.
2. Korbet, SM, Lewis, EJ, Scwartz, MM, Reichlin, M, Evans, J, Rhode. RD. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 2000; 35: 904-914.
3. Hogarth, PM. Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr Opin Immunol 2002; 14: 798-802.
4. Hahn, BH. Mechanisms of disease: antibodies to DNA. N Engl J Med 1998; 338: 1359-1368.
5. Trouw, LA, Groeneveld, TWL, Seelen, MA, et al. Anti-Clq autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular Clq containing immune complexes. J Clin Invest 2004; 114: 679-688.
6. Holers, VM, Girardi, G, Mo, L, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195: 211-220.
7. Merkel, P, Polisson, R, Chang, Y, Skates, S, Niles, J. Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med 1997; 126: 866-873.
8. Cines, DB, Lyss, AP, Reeber, M, Bina, M, DeHoratius, RJ. Presence of complement-fixing anti-endothelial cell antibodies in systemic lupus erythematosus. J Clin Invest 1984; 73: 611-625.
9. Cortés-Hernández, J, Ordi-Ros, J, Labrador, M, et al. Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus 2003; 12: 287-296.
10. Yoo, CW, Kim, M-K, Lee, HS. Predictors of renal outcome in diffuse proliferative lupus nephropathy: data from repeat renal biopsy. Nephrol Dial Transplant 2000; 15: 1604-1608.
11. Chan, TM, Tse, KC, Tang, CSO, Lai, KN, Li, FK. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005; 14: 265-272.
12. Austin, HA, Boumpas, DT, Vaughan, EM, Balow, JE. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 1994; 45: 544-550.
13. Hill, GS, Delahousse, M, Nochy, D, et al. Outcome of relapse in lupus nephritis: Roles of reversal of renal fibrosis and response of inflammation to therapy. Kidney Int 2002: 61: 2176-2186.
14. Esdaile, JM, Levinto, C, Federgreen, W, Hayslett, JP, Kashgarian, M. The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: A study of 87 patients and review of the literature. Q J Med 1989;72: 779-833.
15. Daniel, L, Sichez, H, Giorgi, R, et al.: Tubular lesions and tubular cell adhesion molecules for the prognosis of lupus nephritis. Kidney Int 2001; 60: 2215-2221.
16. Hill, GS, Delahousse, M, Nochy, D, et al. A new morphologic index for the evaluation of renal biopsies in lupus nephritis. Kidney Int 2000; 58: 1160-1173.
17. Cameron, JS. Lupus nephritis. J Am Soc Nephrol 1999; 10: 413-424.
18. D'Amico, G, Minetti, L, Ponticelli, C, et al. Prognostic indicators in idiopathic IgA mesangial nephropathy. Q J Med 1986; 59: 363-378.
19. Isenberg, DA, Manson, JJ, Ehrenstein, MR, Rahman, A. Fisty years of antids-DNA antibodies: are approaching the journey's end? Rheumatology 2007; 46: 1052-1056.
20. Benigni, A, Caroli, C, Longaretti, L, et al. Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus. Arthritis Rheum 2007; 56: 1569-1578.
21. Egerer, K, Feist, E, Rohr, U, Pruss, A, Burmester, GR, Dorner, T. Increased serum soluble CD14, ICAM-1 and E-selectin correlate with disease activity and prognosis in systemic lupus erythematosus. Lupus 2000; 9: 614-621.
22. Mannucci, PM, Vanoli, M, Forza, I, Canciani, MT, Scorza, R. Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis). Haematologica 2003; 88: 914-918.
23. Leibovich, SJ. Vasculopathy and renal injury in lupus erythematosus: does shedding of the endothelial protein C receptor play a role? Kidney Int 2005; 68: 407-408.
24. Ertenli, I, Kiraz, S, Celik, IC, et al. Changes in the concentration and distribution of tissue factor pathway inhibitor in Behcet's disease and systemic lupus erythematosus: effect on the prethrombotic state. Ann Rheum Dis 2001; 60: 1149-1151.
25. Ferro, D, Saliola, M, Meroni, PL, et al. Enhanced monocyte expression of tissue factor by oxidative stress in patients with antiphospholipid antibodies: effect of antioxidant treatment. J Thromb Haemost 2003; 1:523-531.
26. Jamin, C, Dugue, C, Alard, JE, et al. Induction of endothelial cell apoptosis by the binding of anti-endothelial cell antibodies to Hsp60 in vasculitis-associated systemic autoimmune diseases. Arthritis Rheum 2005; 52: 4028-4038.
27. Zheng, L, Sinniah, R. I-Hong Hsu, S. Renal cell apoptosis and proliferation may be linked to nuclear factor-kappaB activation and expression of inducible nitric oxide synthase in patients with lupus nephritis. Hum Pathol 2006; 37: 637-647.
28. Tang, S, Leung, JC, Abe, K, et al. Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo. J Clin Invest 2003; 111: 515-527.
29. Yard, BA, Chorianopoulos, E, Herr, D, Van der Woude, FJ. Regulation of endothelin 1 and transforming growth factor beta 1 production in cultured proximal tubular cells by albumin and heparan sulphate glycosaminoglycans. Nephrol Dial Transplant 2001; 16: 1769-1775.
30. Tiruppathi, C, Naqvi, T, Wu, Y, Vogel, SM, Minshall, RD, Malik, AB. Albumin mediates the transcytosis of myeloperoxidase by means of caveolae in endothelial cells. Proc Natl Acad Sci USA. 2004; 101: 7699-7704.
31. Schiffer, M, Bitzer, M, Roberts, IS, et al. Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 2001; 108: 807-816.
32. Diwakar, R, Pearson, AD, Colville-Nash, P, Brunskill, NJ, Dockrell, ME. The role played by endocytosis in albumin induced secretion of TGF{beta}-1 by proximal tubular epithelial cells. Am J Physiol Renal Physiol; 2007; 292: F1464-1470.
33. Kim, JS, Kim, JG, Moon, MY, et al. Transforming growth factor-betal regulates macrophage migration via RhoA. Blood 2006; 108: 1821-1829.
34. Forino, M, Torregrossa, R, Ceol, M, et al. TGFbetal induces epithelial-mesenchymal transition, but not myofibroblast transdiffer-entiation of human kidney tubular epithelial cells in primary culture. Int J Exp Pathol 2006; 87: 197-208.
35. Docherty, NG, O'Sullivan, OE, Healy, DA, et al. TGF-beta 1-induced EMT can occur independently of its proapoptotic effects and is aided by EGF receptor activation. Am J Physiol Renal Physiol 2006; 290: F1202-F1212.
36. Montinaro, V, Lopez, A, Monno, R, et al. Renal C3 synthesis in idiopathic membranous nephropathy: correlation to urinary C5b-9 excretion. Kidney Int 2000; 57: 137-146.
37. Pratt, JR, Abe, K, Miyazaki, M, Zhou, W, Sacks, SH. In situ localization of C3 synthesis in experimental acute renal allograft rejection. Am J Pathol 2000; 157: 825-831.
38. Bao, L, Wang, Y, Chang, A, et al. Unrestricted C3 activation occurs in Crry-deficient kidneys and rapidly leads to chronic renal failure. J Am Soc Nephrol; 2007; 18: 811-822.
39. Li, J, Deane, JA, Campanale, NV, Bertram, JF, Ricardo, SD. Blockade of p38 mitogen-activated protein kinase and TGF-beta1/Smad signaling pathways rescues bone marrow-derived peritubular capillary endothelial cells in adriamycin-induced nephrosis. J Am Soc Nephrol 2006; 17:2799-2811.
40. Matsumoto, M, Tanaka, T, Yamamoto, T, et al. Hypoperfusion of peritubular capillaries induces chronic hypoxia before progression of tubulointerstitial injury in a progressive model of rat glomerulonephritis. J Am Soc Nephrol 2004; 15: 1574-1581.
41. Hara, A, Wada, T, Furuichi, K, et al. Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis. Kidney Int 2006; 69: 1986-1995.
42. Peterson, KS, Huang, JF, Zhu, J, et al. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcrip-tional profiles of laser-captured glomeruli. J Clin Invest 2004; 113: 1722-1733.
43. Liu, Y, Yang, J. Hepatocyte growth factor: new arsenal in the fights against renal fibrosis? Kidney Int 2006; 70: 238-240 [review].
44. Herrero-Fresneda, I, Torras, J, Franquesa, M, et al. HGF gene therapy attenuates renal allograft scarring by preventing the profibrotic inflammatory-induced mechanisms. Kidney Int 2006; 70: 265-274.
45. Stracke, S, Ernst, F, Jehle, DR, et al. Differentiating and proliferative effects of HGF in renal proximal tubular cells are mediated via different signalling pathways. Nephrol Dial Transplant 1998; 13: 1398-1405.
46. Zhou, YJ, Wang, JH, Zhang, J. Hepatocyte growth factor protects human endothelial cells against advanced glycation end products-induced apoptosis. Biochem Biophys Res Commun 2006; 344: 658-666.
47. Wang, X, Zhou, Y, Kim, HP, et al. Hepatocyte growth factor protects against hypoxia/reoxygenation-induced apoptosis in endothelial cells. J Biol Chem 2004; 279: 5237-5243.
48. Karihaloo, A, O'Rourke, DA, Nickel, C, Spokes, K, Cantley, LG. Differential MAPK pathways utilized for HGF- and EGF-dependent renal epithelial morphogenesis. J Biol Chem 2001; 276: 9166-9173.
49. Jayasankar, V, Woo, YJ, Bish, LT, et al. Gene transfer of hepatocyte growth factor attenuates postinfarction heart failure. Circulation 2003; 108(Suppl. 1): II230-II236.
50. Rampino, T, Gregoriani, M, Camussi, G, et al. Hepatocyte growth factor and its receptor Met are induced in crescentic glomerulonephritis. Nephrol Dial Transplant 2005; 20: 1066-1074.
51. Liu, Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006; 69: 213-217.
52. Gong, R, Rifai, A, Tolbert, EM, Biswas, P, Centracchio, JN, Dworkin, LD. Hepatocyte growth factor ameliorates renal interstitial inflammation in rat remannt kidney by modulatine tubular expression of macrophage chemoattractant protein. 1 and RANTES. J Am Soc Nephrol 2004; 15: 2868-2881.
53. Dai, C, Yang, J, Bastacky, S, Xia, J, Li, Y, Liu, Y. Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice. J Am Soc Nephrol 2004; 15: 2637-2647.
54. Ma, H, Calderon, TM, Fallon, JT, Berman, JW. Hepatocyte growth factor is a survival factor for endothelial cells and is expressed in human atherosclerotic plaques. Atherosclerosis 2002; 164: 79-87.
55. Gong, R, Rifai, A, Dworkin, LD. Hepatocyte growth factor suppresses acute renal inflammation by inhibition of endothelial E-selectin. Kidney Int 2006; 69: 1166-1174.
56. Kuroiwa, T, Iwasaki, T, Imado, T, Sekiguchi, M, Fujimoto, J, Sano, H. Hepatocyte growth factor prevents lupus nephritis in a murine lupus model of chronic graft versus host disease. Arthritis Res Ther 2006; 8: R123.
57. Capuano, A, Costanzi, S, Peluso, G, et al. Hepatocyte growth factor and transforming growth factor betal ratio at baseline can predict early response to cyclophosphamide in systemic lupus erythematosus nephritis. Arthritis Rheum 2006; 54: 3633-3639.
58. Gagliardini, E, Benigni, A. Role of anti-TGF-β antibodies in the treatment of renal injury. Cytokine Growth Factor Rev 2006; 17: 89-96.
59. Li, Y, Wen, X, Spataro, BC, Hu, K, Dai, C, Liu, Y. Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists. J Am Soc Nephrol 2006; 17: 54-65.
60. Li, Y, Spataro, BC, Yang, J, Dai, C, Liu, Y. 1,25-dihydroxyvitamin D inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression. Kidney Int 2005; 68: 1500-1510.
61. Wen, X, Li, Y, Hu, K, Dai, C, Liu, Y. Hepatocyte growth factor receptor signaling mediates the anti-fibrotic action of 9-cis-retinoic acid in glomerular mesangial cells. Am J Pathol 2005; 167: 947-957.
62. Sakiyama, R, Fukuta, K, Matsumoto, K, et al. Stimulation of hepatocyte growth factor production by heparin-derived oligosaccharides. J Biochem (Tokyo) 2007; 141: 653-660.